Execution RisksDespite the positive outlook, there is some execution risk to Zimmer Biomet's financial acquisition goals due to potential cultural, operational, and retention uncertainties.
Financial PerformanceFirst quarter operating margins will likely be down about 250bps compared to 1Q'24.
Market ShareZBH, by their own admission, has lost share to both Stryker and Johnson & Johnson within the hip market due to the growing proportion of hip replacement procedures performed in a direct anterior approach.